



Minutes

**CW Institutional Biosafety Committee
Institutional Biosafety Committee
12/9/2025
1:00 pm
Zoom**

1 Statements of Confidentiality and Conflicts of Interest

Quorum and Meeting Access: The Chair called the meeting to order at 1:01 pm and noted that the meeting was open to the public. Quorum existed at the start of the meeting with 12 voting members present. A quorum was maintained for the entire meeting.

Confidentiality: The Chair reminded the committee that while the meeting is open to the public, the information discussed during the meeting should be treated as confidential.

Conflict of Interest: The Chair asked the committee if any members needed to declare a conflict of interest with respect to any matter on the agenda. The Chair notified committee members that if they had a conflict of interest, they must leave the room during the final discussion and voting on that IBC submission.

2 Attendees

Committee Members Present

Lewis Bowen (Campus Operations)	Biological Safety Officer
Lezi E (Cell Biology Neurobiology and Anatomy)	R/SNA Technology Expert
Benjamin Gantner (Medicine)	Chair
Kunal Gupta (Neurosurgery)	R/SNA Technology Expert
Anna Huppler (Pediatrics)	R/SNA Technology Expert
Eric Jensen (Research Office)	Animal Containment Expert
Tyce Kearl (Medicine)	HGT Expert
	R/SNA Technology Expert
Nikki Lytle (Surgery)	R/SNA Technology Expert
Angela Mathison (Surgery)	R/SNA Technology Expert
Sandy Montes-Gruber (Non-MCW)	Non-Affiliated Member
Amy Pichler (Children's Wisconsin (no MCW faculty appt))	HGT Expert
Laura Stephens (Non-MCW)	Non-Affiliated Member
Matthew Surdel (Medicine)	R/SNA Technology Expert

Committee Members Absent

Kenneth Allen (Research Office)	Alternate Animal Containment Expert, Non-Voting
James Case (Non-MCW)	Non-Affiliated Member
Rebecca Roush (Children's Wisconsin (no MCW faculty appt))	Alternate HGT Expert, Non-Voting
Qizhen Shi (Pediatrics)	R/SNA Technology Expert
Cheryl Singer (Children's Wisconsin (no MCW faculty appt))	Alternate HGT Expert, Non-Voting

3 Meeting Minutes Reviewed at this Meeting

[11/11/2025 \(Zoom\)](#)

Motion:	Minutes Approved
Yes Votes:	12
No Votes:	0
Abstained:	0
Recused:	0
Total Votes:	12

4 New Business

The first and second business items were discussed before the past Meeting Minutes and Administrative Report were reviewed.

1. IBC Standard: *Review of IBC Applications*

The Chair presented the updated Institutional Biosafety Committee (IBC) Standard: *Review of IBC Applications* to the Committee. The updated Standard includes clarification that while all new IBC Applications and renewals are to be reviewed in their entirety, the focus of amendment review should be on the changes that have been made in the IBC Application, as discussed at the November 11, 2025 IBC Meeting. A Committee member asked if amendment reviews should also include sections of the IBC Application that may not have been updated by the Principal Investigator in the submitted amendment but are affected by recently approved or updated IBC Position Statements or have issues that may have been missed in the original approval. The Chair explained that such issues will be identified when applications are reviewed at the time of renewal, so unless the changes made in the current amendment affect the safety of previously approved materials, Committee members should focus on the changes that were made in the amendment. . A Committee member noted she recently reviewed an amendment which added more to the application than was stated in the Amendment Summary, and asked how the reviewers should handle these situations. The Chair stated that reviewers should utilize functionality in eBridge that highlights where changes have been made in the SmartForm. If Committee members need assistance with this, they may contact the IBC Office. The reviewers should also request that the PI update the Amendment Summary to include all changes made. There being no further discussion, upon a motion duly made by a Committee member and seconded, the Committee voted to approve the updates to the IBC Standard.

2. 2026 IBC Meeting Dates

The Chair provided the Institutional Biosafety Committee the meeting dates for 2026.

3. Administrative Report

The Chair asked the Committee Members to review the Administrative Report and then invited discussion. No concerns were raised.

5 Application Reviews

IBC20250045 ION582-CS2 REVEAL

Principal Investigator:	Michael Muriello
Motion:	Decision Pending Changes
Yes Votes:	13
No Votes:	0
Abstained:	0
Recused:	0
Total Votes:	13
NIH Guidelines:	Section III-C-1
Biosafety Level(s):	BSL1, BSL2

Deliberations: (A Committee member joined the meeting at 1:30 pm. Quorum was maintained with 13 voting members.) The Chair introduced this new Institutional Biosafety Committee (IBC) application, and the Primary Reviewer went on to describe the study. This application will support a Phase 3 clinical trial of the antisense oligonucleotide ION582. The primary goal of the study is to restore functional UBE3A expression in the brains of people with Angelman syndrome by pharmacologically “unsilencing” the paternal UBE3A allele via ION582. This mechanism increases UBE3A protein production and aims to improve core neurological and developmental deficits. The Primary and Secondary Reviewer requested a few changes, including that the Principal Investigator confirm that all personnel that will interact with the

5 **Application Reviews**

therapy have completed appropriate training, remove description of the off-site storage of the investigational product, and clarify the risks of exposure to ION582. The Biological Safety Officer had no additional comments. After brief discussion, upon a motion duly made by the Secondary Reviewer and seconded, the Committee voted to approve this application pending the requested changes.

6 **Adjournment**

There being no further business, the meeting was adjourned at 1:39 pm. The next regularly scheduled meeting will be held on Tuesday, January 13, 2026 at 1:00 pm in Zoom.